Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
ViiV’s two-drug Dovato also boasted a high genetic barrier to the development of viral resistance.
The single-tablet regimen is now approved for previously treated people with an undetectable viral load.
A high success rate was seen halfway into a 48-week study in which people with HIV started treatment within two weeks of diagnosis.
A recent small study examined pairings of antiretrovirals and statins or blood pressure medications.
Findings suggest exposure to antiretrovirals, including dolutegravir, during pregnancy does not raise the risk of neural tube defects.
Researchers at George Washington University take a look.
The latest revision recognizes the importance of treatment as prevention.
Here are the HIV treatment news stories with the most views this year.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Updating previous, similar findings, researchers have now reported on 96-week data from a pair of ongoing trials.
A late-stage trial randomized people taking a stable HIV regimen to switch to Dovato or stay on their current antiretrovirals.
The Food and Drug Administration has approved a new treatment for people living with HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.